Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
P. Mease,L. Coates,14 Authors,D. Gladman
2018 · DOI: 10.1016/S0140-6736(18)32483-8
The Lancet · 165 Citations
TLDR
Filgotinib is efficacious for the treatment of active psoriatic arthritis, and no new safety signals were identified.